---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-106265"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:44:46.895915+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics Appoints Andrew Scott as VP of Corporate Communications

## Summary
- Andrew Scott appointed VP of Corporate Communications effective November 4, 2025.
- Scott will oversee IR, capital markets strategy, and licensing partnerships.
- He joins from ThinkEquity LLC, where he was Managing Director of Investment Banking.
- Scott has helped raise approximately $3 billion across life-sciences transactions.

## SEC filing metadata
- accession: 0001213900-25-106265
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390025106265/0001213900-25-106265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390025106265/ea0264083-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-106265
- JSON: https://secwatch.observer/filing/0001213900-25-106265.json
- Plain text: https://secwatch.observer/filing/0001213900-25-106265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.